Anuja Java, MD

In the final segment of this 5-part HCPLive RX Review, experts discuss real-world barriers to implementing new C3G therapies and lingering unmet needs.

In part 4 of this 5-part HCPLive RX Review, experts discuss how the availability of new therapeutic options are changing the treatment paradigm in C3G.

In part 3 of this 5-part HCPLive RX Review, experts discuss VALIANT data supporting pegcetacoplan’s approval and how they compare to iptacopan.

In part 2 of this 5-part HCPLive RX Review, experts discuss how to utilize the newly FDA-approved therapies for treating C3G and what questions remain.

In part 1 of this 5-part HCPLive RX Review, experts discuss the current therapeutic landscape for C3G following 2 notable FDA approvals.

Panelists summarize the key points discussed regarding the evolving landscape of IgA nephropathy treatments, highlighting the importance of addressing unmet needs, the significance of reducing proteinuria, and the role of emerging therapies in modifying disease progression, ultimately emphasizing the necessity for personalized treatment approaches and effective communication with patients to improve clinical outcomes.

Panelists discuss how shared decision-making is essential when considering emerging treatments vs established therapies, emphasizing the importance of aligning treatment choices with patient preferences and values to enhance adherence and optimize outcomes in IgA nephropathy care.

Panelists discuss how the approval of atrasentan is expected to significantly affect the treatment landscape for IgA nephropathy by offering a novel therapeutic option that targets both proteinuria reduction and the underlying immune dysregulation associated with the disease.

Panelists discuss how the NefIgArd study findings contribute valuable insights into the efficacy of emerging therapies for IgA nephropathy, emphasizing their role in reducing proteinuria and improving patient outcomes.

Panelists discuss how the PROTECT study’s results enhance the understanding of emerging therapies for IgA nephropathy, focusing on their potential to reduce proteinuria and modify disease progression.

Panelists discuss how the ALIGN trial data inform the development and potential impact of emerging therapies for IgA nephropathy, particularly focusing on their efficacy in reducing proteinuria and addressing disease pathology.

Panelists discuss how the ALIGN trial data inform the development and potential impact of emerging therapies for IgA nephropathy, particularly focusing on their efficacy in reducing proteinuria and addressing disease pathology.

Panelists discuss how emerging therapies are expected to address the unmet need for treatments that not only reduce proteinuria but also target the underlying immune dysfunction associated with IgA nephropathy.

Panelists discuss how adverse effects associated with corticosteroids can significantly affect patient adherence and quality of life, emphasizing the need for future therapies to strike a balance between efficacy and a more tolerable adverse effect profile.

Panelists discuss how current treatments for IgA nephropathy often fall short in addressing the root cause, specifically abnormal IgA production and deposition, and highlight the consequences of prioritizing symptom management, such as proteinuria reduction, over targeting the disease’s underlying pathology.

Panelists discuss how the current treatment landscape for IgA nephropathy presents significant unmet needs, particularly in addressing the underlying causes of the disease and improving patient outcomes.

Panelists discuss how clinicians can effectively shift treatment strategies for IgA nephropathy from merely managing symptoms to actively targeting the root causes of the disease.

Panelists discuss how the reduction of proteinuria is integral to the broader treatment goals for IgA nephropathy, highlighting evidence that supports its role in preventing long-term kidney damage.

Panelists discuss how the primary treatment goals for patients with IgA nephropathy evolve based on the stage of the disease, emphasizing the importance of tailoring strategies to individual patient needs.

Panelists discuss how integrating additional biomarkers with proteinuria measurements can enhance the diagnostic accuracy for IgA nephropathy.

Panelists discuss how clinicians determine the significance of proteinuria in assessing patients for potential IgA nephropathy (IgAN), including the levels and patterns that prompt further investigation and the specific diagnostic red flags that may suggest IgAN over other kidney disorders.

Panelists discuss how clinicians determine the significance of proteinuria in assessing patients for potential IgA nephropathy (IgAN), including the levels and patterns that prompt further investigation and the specific diagnostic red flags that may suggest IgAN over other kidney disorders.

Panelists discuss how clinicians can differentiate IgA nephropathy from other glomerular diseases, such as lupus nephritis and membranous nephropathy, that may present with similar clinical features.

Panelists discuss how misdiagnosis and delayed diagnosis of IgA nephropathy occur, highlighting the primary barriers to timely detection and strategies to overcome these challenges.

Panelists discuss how IgA nephropathy affects patients’ quality of life, addressing both the physical symptoms and the emotional challenges associated with the condition.

Panelists discuss the importance of screening and monitoring family members of individuals with IgA nephropathy, noting that up to 15% of cases are familial and outlining recommendations for the frequency of such assessments.

Panelists discuss potential biomarkers and clinical indicators that can aid in predicting disease outcomes for individual patients with IgA nephropathy.

Panelists discuss the immune system dysregulation underlying IgA nephropathy and highlight how this mechanism differs from those seen in other glomerular diseases.

Panelists discuss the progressive nature of immunoglobulin AIgA nephropathy (IgAN) and identify key factors that may accelerate its progression toward end-stage renal disease (ESRD).

Panelists discuss how IgA nephropathy presents in patients, often remaining asymptomatic until significant progression occurs, and explore the various subtypes that exhibit distinct clinical features.